MALAT1-mediated upregulation of STAT3 also correlates with its reported role in enhancing the expression of MRP1 (ATP binding cassette subfamily C member 1) and MDR1 (ATP binding cassette subfamily B member 1) through STAT3 activation, in turn driving cisplatin-resistance in lung cancer [99]. This evidence concerns the gene STAT3 and lung carcinoma.